Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD.Methods: We conducted a multicenter cross-sectional survey amon...

Full description

Bibliographic Details
Main Authors: Lingya Yao, Xiao Zhu, Bule Shao, Rongbei Liu, Zhilun Li, Lexi Wu, Jin Chen, Qian Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Pharmacology
Subjects:
Crohn’s disease
ustekinumab (UST)
preference
Chinese patients
multicenter cross-sectional study
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.736149/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.736149/full

Similar Items